NCT00246961已完成不适用
Arimidex: Reason for and Effect of Change From Tamoxifen
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 200
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal
- •Hormone sensitive breast cancer
- •Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
排除标准
- •Visceral metastases
- •Patients with signs of progression at the moment of changing therapy
- •Patients who have used other endocrine treatments for breast cancer besides tamoxifen
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast CancerBreast CancerNCT00692289AstraZeneca1,510
已完成
3 期
ATAC - Quality of Life Sub-ProtocolQuality of LifeNCT00784680AstraZeneca308
尚未招募
不适用
QOL After SURGERY and ADJUVANT TreatmentCarcinoma, Non-Small-Cell LungQuality of LifeNCT06115239University of Salamanca200
已完成
不适用
Greek Study of the Quality of Life in Patients With Psoriasis Treated With AdalimumabPsoriasisNCT01077128AbbVie (prior sponsor, Abbott)500
进行中（未招募）
3 期
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)Symptomatic Non-Obstructive Hypertrophic CardiomyopathyNCT06081894Cytokinetics500